VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses
Diabetic nephropathy (DN) is considered the primary causes of end-stage renal disease (ESRD) and is related to abnormal glycolipid metabolism, hemodynamic abnormalities, oxidative stress and chronic inflammation. Antagonism of vascular endothelial growth factor B (VEGF-B) could efficiently ameliorat...
Saved in:
Main Authors: | Yilan Shen (Author), Wei Chen (Author), Lei Han (Author), Qi Bian (Author), Jiajun Fan (Author), Zhonglian Cao (Author), Xin Jin (Author), Tao Ding (Author), Zongshu Xian (Author), Zhiyong Guo (Author), Wei Zhang (Author), Dianwen Ju (Author), Xiaobin Mei (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glabridin, a bioactive component of licorice, ameliorates diabetic nephropathy by regulating ferroptosis and the VEGF/Akt/ERK pathways
by: Hongtao Tan, et al.
Published: (2022) -
Research progress of interleukin-15 in cancer immunotherapy
by: Menghan Cai, et al.
Published: (2023) -
The role of interleukin-19 in diabetic nephropathy
by: Khaled A Elhefnawy, et al.
Published: (2019) -
Targeting interleukin-22 for cancer therapy
by: Anamarija Markota, et al.
Published: (2018) -
Immunoexpression of Interleukin-22 and Interleukin-23 in Oral and Cutaneous Lichen Planus Lesions: A Preliminary Study
by: Jun Chen, et al.
Published: (2013)